Review of Current Guidelines for Systemic „Non-biological“ Therapy of Psoriasis Clinical Practice
Guidelines of the Board of ČDS ČLS JEP

Česká verzia

Authors: P. Cetkovská ¹; M. Kojanová ²; P. Arenberger ³; J. Fabianová ⁴
Authors place of work: Dermatovenerologická klinika FN a LF UK, Plzeň přednosta prof. MUDr. Karel Pizinger, CSc. ¹; Dermatovenerologická klinika VFN a 1. LF UK, Praha přednosta prof. MUDr. Jiří Štork, CSc. ²; Dermatovenerologická klinika FNKV a 3. LF UK, Praha přednosta prof. MUDr. Petr Arenberger, DrSc., MBA ³; Farmakoterapie, Praha ⁴
Published in the journal: Čes-slov Derm, 92, 2017, No. 1, p. 3-16
Category: Reviews (Continuing Medical Education)

Summary

Psoriasis is a chronic genetically determined immunologically mediated inflammatory condition with important systemic component (cardiovascular diseases, metabolic syndrome etc.). Local therapy and phototherapy is usually recommended for mild psoriasis. When this treatment is not effective, not tolerated or contraindicated, as well as in patients with severe disease or significantly decreased quality of life the systemic therapy is prescribed. Current range of systemic therapy in the Czech Republic includes non-biological agents (methotrexate, ciclosporin, acitretin), phototherapy and biological agents (adalimumab, etanercept, infliximab, ustekinumab, secukinumab). Presented recommendation for „non-biological“ systemic therapy of adult patients with moderate to severe psoriasis takes into account the European guidelines published in 2009 and their revised version from the year 2015 and international consensus adjusted upon clinical practice in the Czech Republic and current drug package inserts information (SPC).

Key words:
psoriasis – phototherapy – systemic treatment – methotrexate – ciclosporin – acitretin

Zdroje

1. ARENBERGER, P. Setkání Center biologické léčby psoriázy. Čes-slov Derm, 2016, 91, p. 154–204.

2. BOEHNCKE, W. H., BOEHNCKE, S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly, 2014, 144, p. 139–168.

3. ETTLER, K. Fototerapie psoriázy. Lékařské listy. 2013, http://zdravi.euro.cz/clanek/priloha-lekarske-listy/fototerapie-psoriazy-469159.

4. FELDMAN, S. R., KOO, J. Y., MENTER, A. et al. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol, 2005, 53, p. 101–107.

5. GELFAND, JM., TROXEL, AB., LEWIS, JD. et al. The risk of mortality in patients with psoriasis: results from a population based study. Arch Dermatol, 2007, 143, p. 1493–1499.

6. KOLIOS, A. G., YAWALKAR, N., ANLIKER, M. et al. Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. Dermatology, 2016, 232, p. 385–406.

7. LEBWOHL, M. G., BACHELEZ, H., BARKER, J. et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol, 2014, 70, p. 871–881.

8. MENTER, A., KORMAN, N. J., ELMETS, C. A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol, 2009, 61, p. 451–485.

9. MENTER, A., KORMAN, N. J., ELMETS, C. A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol, 2010, 62, p. 114–135.

10. MROWIETZ, U., DE JONG, E. M., KRAGBALLE, K. et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol, 2014, 28, p. 438–453.

11. MROWIETZ, U., KRAGBALLE, K., REICH, K. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res, 2011, 303, p. 1–10.

12. NALDI, L., GRIFFITHS, CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. British J Dermatol, 2005, 152, p. 597–615.

13. NAST, A., BOEHNCKE, W. H., MROWIETZ, U. et al. Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges, 2012, 10(Suppl 2), p. S1–S95.

14. NAST, A., GISONDI, P., ORMEROD, A. D. et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Long version – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol, 2015, 29, p. 2277–2294

15. National Clinical Guideline Centre. Psoriasis: Assessment and management of psoriasis. Clinical Guideline. Methods, evidence and recommendations. Issued: October 2012.

16. Neotigason 10 mg, 25 mg, Souhrn informací o přípravku, 2016.

17. OGDIE, A., WEISS, P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am, 2015, 41, p. 545–568.

18. PATHIRANA, D., ORMEROD, A. D., SAIAG, P. et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol, 2009, 23(Suppl 2), p. 1–70.

19. PRODANOVICH, S., MA, F., TAYLOR, J. R. et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol, 2005, 52, p. 262–267.

20. RAJAPPA, M., RATHIKA, S., MUNISAMY, M. et al. Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol, 2015, 29, p. 69–76.

21. Sandimmun Neoral 25 mg, 50 mg, 100 mg, Souhrn informací o přípravku, 2015.

22. Trexan 2,5 mg, 10 mg tablety, Souhrn informací o přípravku, 2015.

23. www.dermakalk.cz